Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 10/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 10/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 10/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 10/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 10/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 10/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151495 | 0.97 | PPARG (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5151311 | 0.95 | MRGPRX4 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5149581 | 0.92 | MRGPRX4 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5152540 | 0.90 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5154734 | 0.85 | PSEN1 (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5156572 | 0.85 | MRGPRX4 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5154633 | 0.85 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5149371 | 0.85 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5155221 | 0.84 | KDM4E (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL5154902 | 0.82 | MCL1 (0.55) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | claimed |
| WO-2007071456-A1 | FLUORENES AND CARBAZOLES AS LIGANDS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | claimed |
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-08-23 | — | — | US | disclosed |
| WO-2007071456-A1 | FLUORENES AND CARBAZOLES AS LIGANDS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197524-A1 | Fluorenes and carbazoles as ligands of the EP2 receptor | PTGER2, PTGER1, PTGDR2 | PSEN1 2971/4885PSEN2 1240/4885APH1B 3232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.